Interpace Biosciences (IDXG)
(Delayed Data from OTC)
$1.68 USD
+0.05 (3.38%)
Updated Sep 20, 2024 02:41 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Interpace Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 5 | 3 | 3 | 2 |
Receivables | 5 | 5 | 6 | 8 | 10 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 3 | 3 | 4 |
Total Current Assets | 10 | 12 | 12 | 14 | 16 |
Net Property & Equipment | 1 | 0 | 6 | 7 | 7 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 1 | 16 | 20 | 42 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 13 | 16 | 38 | 46 | 69 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 5 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 3 | 5 | 5 |
Current Portion Long-Term Debt | 0 | 3 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 10 | 10 | 12 | 13 | 12 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 1 | 1 | 1 |
Total Current Liabilities | 17 | 14 | 16 | 18 | 17 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 4 | 11 | 9 | 0 | 3 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 5 | 6 | 6 | 7 |
Minority Interest (Liabilities) | 47 | 47 | 47 | 47 | 26 |
Total Liabilities | 75 | 79 | 81 | 75 | 56 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 188 | 188 | 186 | 184 | 183 |
Retained Earnings | -248 | -249 | -227 | -212 | -168 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 2 | 2 | 2 | 2 | 2 |
Total Shareholder's Equity | -62 | -63 | -42 | -29 | 13 |
Total Liabilities & Shareholder's Equity | 13 | 16 | 38 | 46 | 69 |
Total Common Equity | -62 | -63 | -42 | -29 | 13 |
Shares Outstanding | 4.30 | 4.20 | 4.10 | 4.00 | 3.80 |
Book Value Per Share | -14.34 | -15.02 | -10.35 | -7.27 | 3.43 |
Fiscal Year End for Interpace Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2 | 3 | 4 | 5 | 5 |
Receivables | 6 | 5 | 5 | 5 | 6 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 2 | 2 | 2 |
Total Current Assets | 10 | 9 | 10 | 11 | 13 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 13 | 12 | 13 | 14 | 16 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 7 | 8 | 5 | 0 | 0 |
Accounts Payable | 2 | 1 | 2 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 2 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 10 | 9 | 10 | 10 | 10 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 1 | 1 | 1 |
Total Current Liabilities | 19 | 19 | 17 | 12 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 1 | 4 | 12 | 11 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 5 | 5 | 5 | |
Minority Interest (Liabilities) | 47 | 47 | 47 | 47 | 47 |
Total Liabilities | 72 | 73 | 75 | 77 | 78 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 188 | 188 | 188 | 188 | 188 |
Retained Earnings | -246 | -248 | -248 | -249 | -248 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 2 | 2 | 2 | 2 | 2 |
Total Shareholder's Equity | -59 | -61 | -62 | -63 | -62 |
Total Liabilities & Shareholder's Equity | 13 | 12 | 13 | 14 | 16 |
Total Common Equity | -59 | -61 | -62 | -63 | -62 |
Shares Outstanding | 4.30 | 4.30 | 4.30 | 4.30 | 4.30 |
Book Value Per Share | -13.73 | -14.22 | -14.34 | -14.58 | -14.47 |